Skip to main content

European network for vaccine evaluation in primates: combined vector immunisations for aids vaccine development

Objective

Important vaccine against human pathogens, e.g. poliomyelitis virus and hepatitis B virus, could only be developed by trials in non-human primates. BSL 2 or 3 facilities suitable for housing infected non-human primates are scarce in Europe. No single European institute can house sufficient animals to generate statistically reliable results comparing multiple vaccine strategies. Thus, eight European primate facilities will establish a network for preclinical vaccine evaluation in non-human primates. To contribute to AIDS vaccine development and to prove our capacity to conduct highly co-ordinated vaccine trials, we propose to optimise combination of three genetically- based vaccines in a multi-centre experiment. Our concerted approach will optimise scarce European resources, improve our ability to conduct preclinical vaccine trials in relevant challenge models and enhance the global competitiveness of European vaccine developers.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

DEUTSCHES PRIMATENZENTRUM GMBH
Address
4,Kellnerweg 4
37077 Göttingen
Germany

Participants (7)

COMMISSARIAT A L'ENERGIE ATOMIQUE
France
Address
Rue De La Federation 31-33
75015 Paris
FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE
Netherlands
Address
Lange Kleiweg 139
2288 GJ Rijswijk Zh
Head of the Unit of Foodborne Zoonoses and Veterinary Epidemiology
Italy
Address
Viale Regina Elena 299
00161 Rome
MICROBIOLOGICAL RESEARCH AUTHORITY
United Kingdom
Address
Porton Down
SP4 0JG Salisbury
NATIONAL BIOLOGICAL STANDARDS BOARD
United Kingdom
Address
Blanche Lane, South Mimms
Potters Bar
PAUL-EHRLICH-INSTITUT, FEDERAL AGENCY FOR SERA AND VACCINES
Germany
Address
Paul-ehrlich-strasse 51-59
63225 Langen
SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL
Sweden
Address
Nobels Vaeg 18
Solna